<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002045</url>
  </required_header>
  <id_info>
    <org_study_id>014E</org_study_id>
    <secondary_id>15</secondary_id>
    <nct_id>NCT00002045</nct_id>
  </id_info>
  <brief_title>A Prospective Double-Blind Study of Retrovir in Early HIV Infection</brief_title>
  <official_title>A Prospective Double-Blind Study of Retrovir in Early HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerance of chronic administration of Retrovir (AZT) to adult&#xD;
      patients with early manifestations of HIV disease. To assess the efficacy of AZT therapy in&#xD;
      the treatment of HIV disease in these patients.&#xD;
&#xD;
      (12/01/89) Information supplied by drug company update. Study discontinued due to positive&#xD;
      data from ACTG 016.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Electron beam therapy to an area of less than 100 cm2.&#xD;
&#xD;
        Patient must have signs and symptoms of HIV infection confined to those of stages WRII-V or&#xD;
        CDC groups III IV-A, IV-C-2 (except recurrent Salmonella bacteremia, nocardiosis, or&#xD;
        disseminated/extrapulmonary Mycobacterium tuberculosis), and IV-E (except diffuse&#xD;
        interstitial lymphoid pneumonitis).&#xD;
&#xD;
          -  Patient must be able to give informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Evidence of nervous system dysfunction caused by factors other than HIV infection,&#xD;
             including chronic alcohol or drug abuse.&#xD;
&#xD;
          -  Present or prior known AIDS-defining opportunistic infections, lymphomas, or&#xD;
             malignancies based on CDC criteria.&#xD;
&#xD;
          -  Present or prior known systemic opportunistic diseases most recently included in the&#xD;
             expanded CDC definition of AIDS:&#xD;
&#xD;
          -  extrapulmonary or disseminated Mycobacterium tuberculosis infections, recurrent&#xD;
             nontyphoidal Salmonella septicemia, coccidioidomycosis, diffuse interstitial lymphoid&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Evidence of compromised bone marrow function defined by specified lab values.&#xD;
&#xD;
          -  Evidence of HIV neurologic disease.&#xD;
&#xD;
          -  Evidence of HIV-associated &quot;wasting syndrome&quot;.&#xD;
&#xD;
          -  Hypersensitivity to zidovudine (AZT).&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Cytotoxic chemotherapeutic agents.&#xD;
&#xD;
          -  Steroids.&#xD;
&#xD;
          -  Interferon or immunomodulating agents.&#xD;
&#xD;
          -  Any antiretroviral drug including, but not limited to zidovudine (AZT), ribavirin,&#xD;
             HPA23, AL 721, or phosphonoformate.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Evidence of nervous system dysfunction caused by factors other than HIV infection,&#xD;
             including chronic alcohol or drug abuse. Present or prior known AIDS-defining&#xD;
             opportunistic infections, lymphomas, or malignancies based on CDC criteria. Present or&#xD;
             prior known systemic opportunistic diseases most recently included in the expanded CDC&#xD;
             definition of AIDS:&#xD;
&#xD;
          -  extrapulmonary or disseminated Mycobacterium tuberculosis infections, recurrent&#xD;
             nontyphoidal Salmonella septicemia, coccidioidomycosis, diffuse interstitial lymphoid&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Evidence of compromised bone marrow function defined by specified lab values. Evidence&#xD;
             of HIV neurologic disease.&#xD;
&#xD;
          -  Evidence of HIV-associated wasting syndrome.&#xD;
&#xD;
          -  Hypersensitivity to retrovir.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Interferon.&#xD;
&#xD;
          -  Immunomodulating agents.&#xD;
&#xD;
          -  Myelosuppressive drugs.&#xD;
&#xD;
          -  Nephrotoxic agents.&#xD;
&#xD;
          -  Other experimental chemotherapy.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Treatment with radiation therapy (with the exception of electron beam therapy to an&#xD;
             area of less than 100 cm2).&#xD;
&#xD;
        Chronic alcohol or drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Glaxo Wellcome Inc</name>
      <address>
        <city>Research Triangle Park</city>
        <state>North Carolina</state>
        <zip>27709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 1989</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Prospective Studies</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

